Table 2. Association between MBL2 SNPs and risk of glioma in 3 prospective cohort studies.
| SNP | Cases | Controls | ORa | 95% CI | P |
| n (%) | n (%) | ||||
| rs10824792 | |||||
| AA | 40 (28.8) | 139 (34.1) | 1.0 | ref. | |
| AG | 73 (52.5) | 195 (47.8) | 1.30 | (0.83–2.02) | |
| GG | 26 (18.7) | 74 (18.1) | 1.22 | (0.70–2.16) | 0.39 |
| rs11595876 | |||||
| AA | 120 (86.3) | 372 (90.5) | 1.0 | ref. | |
| AG | 18 (12.9) | 35 (8.5) | 1.60 | (0.87–2.92) | |
| GG | 1 (0.7) | 0. 4 (1.0) | 0.73 | (0.08–6.65) | 0.26 |
| rs930508 | |||||
| CC | 94 (68.1) | 262 (63.7) | 1.0 | ref. | |
| CG | 40 (29.0) | 132 (32.1) | 0.86 | (0.56–1.32) | |
| GG | 4 (2.9) | 17 (4.1) | 0.65 | (0.21–1.98) | 0.34 |
| rs1838066 | |||||
| AA | 50 (35.7) | 176 (42.8) | 1.0 | ref. | |
| AG | 72 (51.4) | 175 (42.6) | 1.45 | (0.95–2.20) | |
| GG | 18 (12.9) | 60 (14.6) | 1.05 | (0.57–1.95) | 0.43 |
| rs1982266b | |||||
| GG | 53 (37.9) | 113 (27.8) | 1.0 | ref. | |
| GA | 70 (50.0) | 193 (47.2) | 0.78 | (0.51–1.20) | |
| AA | 17 (12.1) | 102 (25.1) | 0.36 | (0.20–0.66) | 0.003 |
| rs1800450c | |||||
| CC | 81 (69.8) | 271 (78.6) | 1.0 | ref. | |
| CT | 32 (27.6) | 71 (20.6) | 1.51 | (0.93–2.45) | |
| TT | 3 (2.6) | 3 (0.9) | 3.44 | (0.68–17.4) | 0.04 |
| rs7096206d | |||||
| CC | 86 (61.9) | 238 (59.5) | 1.0 | ref. | |
| CG | 47 (33.8) | 139 (34.8) | 0.95 | (0.63–1.44) | |
| GG | 6 (4.3) | 23 (5.8) | 0.74 | (0.29–1.88) | 0.58 |
| rs11003125e | |||||
| CC | 50 (41.3) | 146 (42.0) | 1.0 | ref. | |
| CG | 55 (45.5) | 146 (42.0) | 1.09 | (0.70–1.71) | |
| GG | 16 (13.2) | 56 (16.1) | 0.82 | (0.43–1.56) | 0.72 |
a
Odds ratio adjusted for age and study (cohort; sex).
b
rs4935047 and rs10824793 are in complete LD with rs1982266 and thus results are not shown.
c
Also known as Ex1-27G>A; A/B.
d
Also known as −289 G>C; X/Y.
e
Also known as −618 G>A; H/L.